Search

Your search keyword '"Port, Kerstin"' showing total 159 results

Search Constraints

Start Over You searched for: Author "Port, Kerstin" Remove constraint Author: "Port, Kerstin"
159 results on '"Port, Kerstin"'

Search Results

1. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

2. Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

3. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

5. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

6. Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection.

7. Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

11. Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response

12. Unusual HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

13. Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

15. Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.

18. Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial.

23. Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience

24. Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study

26. Bulevirtide treatment of hepatitis D in Germany : multicentre real-world experience

27. Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment

30. Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C.

31. Distinct Immune Imprints of Post–Liver Transplantation Hepatitis C Persist Despite Viral Clearance

32. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

34. sj-pdf-2-ueg-10.1177_2050640620976991 - Supplemental material for Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients

35. sj-pdf-3-ueg-10.1177_2050640620976991 - Supplemental material for Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients

36. sj-pdf-1-ueg-10.1177_2050640620976991 - Supplemental material for Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients

37. SAT-156 - Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response

38. SAT-152 - Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

41. Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C

42. Imprint of unconventional T‐cell response in acute hepatitis C persists despite successful early antiviral treatment.

44. Improved pharmakodynamics after intravenous application of PEG-interferon alfa-2a in patients with chronic GT1 hepatitis C virus infection and null response to prior peginterferon and ribavirin treatment. The IVAN study: 799

45. Pegylated-Interferon-a-2a plus Tenofovir or Placebo for the treatment of hepatitis delta: First results of the HIDIT-2 study: 24

50. Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study

Catalog

Books, media, physical & digital resources